RecruitingPHASE1, PHASE2NCT06541262
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Studying Embryonal rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Milton S. Hershey Medical Center
- Principal Investigator
- Chandrika Behura, MDPenn State Health Children's Hospital
- Intervention
- Silmitasertib(drug)
- Enrollment
- 104 enrolled
- Eligibility
- 30 years · All sexes
- Timeline
- 2024 – 2035
Study locations (20)
- University of Alabama/Children's of Alabama, Birmingham, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Rady Children's Hospital, San Diego, California, United States
- University of Florida, Gainesville, Florida, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- Arnold Palmer Hospital for Children, Orlando, Florida, United States
- St. Joseph's Children's Hospital, Tampa, Florida, United States
- Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States
- Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine, Louisville, Kentucky, United States
- Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States
- Cardinal Glennon Children's Medical Center, St Louis, Missouri, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
- Hasbro Children's Hospital, Providence, Rhode Island, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06541262 on ClinicalTrials.govOther trials for Embryonal rhabdomyosarcoma
Additional recruiting or active studies for the same condition.